Conestoga Capital Advisors LLC Cuts Stock Position in LeMaitre Vascular, Inc. $LMAT

Conestoga Capital Advisors LLC decreased its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 1.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,574,688 shares of the medical instruments supplier’s stock after selling 28,840 shares during the quarter. LeMaitre Vascular comprises about 2.2% of Conestoga Capital Advisors LLC’s investment portfolio, making the stock its 19th biggest holding. Conestoga Capital Advisors LLC owned about 6.96% of LeMaitre Vascular worth $137,801,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Geneva Capital Management LLC increased its holdings in shares of LeMaitre Vascular by 6.0% during the second quarter. Geneva Capital Management LLC now owns 915,238 shares of the medical instruments supplier’s stock valued at $76,010,000 after acquiring an additional 51,489 shares in the last quarter. Congress Asset Management Co. boosted its stake in LeMaitre Vascular by 2.7% in the 3rd quarter. Congress Asset Management Co. now owns 692,266 shares of the medical instruments supplier’s stock worth $60,580,000 after purchasing an additional 18,298 shares in the last quarter. First Trust Advisors LP grew its position in LeMaitre Vascular by 52.7% during the 2nd quarter. First Trust Advisors LP now owns 612,028 shares of the medical instruments supplier’s stock valued at $50,829,000 after purchasing an additional 211,280 shares during the last quarter. Geode Capital Management LLC increased its stake in LeMaitre Vascular by 3.0% during the 2nd quarter. Geode Capital Management LLC now owns 519,792 shares of the medical instruments supplier’s stock valued at $43,174,000 after purchasing an additional 15,036 shares in the last quarter. Finally, Envestnet Asset Management Inc. increased its stake in LeMaitre Vascular by 6.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 304,556 shares of the medical instruments supplier’s stock valued at $25,293,000 after purchasing an additional 19,447 shares in the last quarter. 84.64% of the stock is owned by institutional investors.

LeMaitre Vascular Trading Down 0.0%

NASDAQ:LMAT opened at $85.00 on Monday. The company has a market cap of $1.93 billion, a PE ratio of 36.64, a price-to-earnings-growth ratio of 1.89 and a beta of 0.68. The company has a current ratio of 13.58, a quick ratio of 11.45 and a debt-to-equity ratio of 0.44. The company has a 50 day simple moving average of $84.76 and a two-hundred day simple moving average of $87.33. LeMaitre Vascular, Inc. has a 12 month low of $71.42 and a 12 month high of $105.55.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.05. LeMaitre Vascular had a return on equity of 14.06% and a net margin of 22.14%.The firm had revenue of $61.05 million for the quarter, compared to analysts’ expectations of $62.18 million. During the same period in the prior year, the firm earned $0.49 EPS. The company’s revenue was up 11.4% compared to the same quarter last year. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS and its Q4 2025 guidance at 0.640-0.690 EPS. Research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, December 4th. Shareholders of record on Thursday, November 20th were paid a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date was Thursday, November 20th. LeMaitre Vascular’s payout ratio is currently 34.48%.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, December 6th. Wells Fargo & Company decreased their price objective on shares of LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating for the company in a report on Friday, November 7th. Barrington Research reiterated an “outperform” rating and set a $95.00 target price on shares of LeMaitre Vascular in a research note on Wednesday, October 15th. Zacks Research lowered LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 1st. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of LeMaitre Vascular in a report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, LeMaitre Vascular currently has a consensus rating of “Moderate Buy” and an average target price of $100.20.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.